Agenus con­tin­ues part­ner­ship talks for an­ti-CT­LA-4 com­bo with new Phase 2 da­ta

Five months af­ter the FDA blocked its plans for ac­cel­er­at­ed ap­proval, Agenus is mov­ing ahead with dis­cus­sions with po­ten­tial phar­ma part­ners to chart a more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland